ArticleRadiology advances2024
Pathologic outcome of incidentally detected tracer-avid lesions in
Article in Radiology advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.European radiology · 2026Article
- Prostate-specific Membrane Antigen-PET/CT in Nonprostatic Malignancies: Potential Applications in Theranostics.Clinical nuclear medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate-specific membrane antigen (PSMA) PET is effective in identifying prostate cancer metastases. However, PSMA PET uptake has also been described in other lesions, including nonprostate malignancies and benign processes. Purpose: To identify causes of unexpected radiopharmaceutical accumulation on PSMA PET. Materials and Methods: A total of 2,054 study reports representing 1,873 unique patients who had undergone Results: In 48 patients, the PSMA ligand-avid incidental lesions revealed 19 cases of second malignancies, 17 cases of prostate cancer, and 13 cases of benign lesions. The most common lesion locations were lung (14), thyroid (14), lymph nodes (8), and bowel (4). Benign lesions exhibited lower molecular imaging PSMA scores (median: 1; interquartile range [IQR]: 1.00-1.25; Conclusion: Features that influence the probability of an incidental lesion representing a malignancy include lesion location, reason for the PSMA PET/CT study, and associated imaging features (size, standardized uptake value maximum, and molecular imaging PSMA score).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.